BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Actinium (225Ac) oxodotreotide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Actinium (225Ac) oxodotreotide\, from Cli
 nicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05477576-9190@assetmemo.bio
DTSTAMP:20261121T005038Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Actinium (225Ac) oxodotreotide: Phase 3 readout est. (NCT05477576)
DESCRIPTION:Actinium (225Ac) oxodotreotide\, phase 3.\nStudy: Study of RYZ1
 01 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET
  That Has Progressed Following 177Lu-SSA Therapy\nEstimated primary comple
 tion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 actinium-225ac-oxodotreotide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05477576
URL:https://assetmemo.bio/drug/actinium-225ac-oxodotreotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150806-9190@assetmemo.bio
DTSTAMP:20261121T005038Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Actinium (225Ac) oxodotreotide: Phase 1/2 readout est. (NCT07150806
 )
DESCRIPTION:Actinium (225Ac) oxodotreotide\, phase 1/2.\nStudy: RYZ101 for 
 the Treatment of Progressive or Recurrent Intracranial Meningioma\nEstimat
 ed primary completion: 31 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/actinium-225ac-oxodotreotide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07150806
URL:https://assetmemo.bio/drug/actinium-225ac-oxodotreotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05595460-9190@assetmemo.bio
DTSTAMP:20261121T005038Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Actinium (225Ac) oxodotreotide: Phase 1 readout est. (NCT05595460)
DESCRIPTION:Actinium (225Ac) oxodotreotide\, phase 1.\nStudy: Study of RYZ1
 01 in Combination With SoC in Subjects With SSTR+ ES-SCLC\nEstimated prima
 ry completion: July 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/actinium-225ac-oxodotreotide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05595460
URL:https://assetmemo.bio/drug/actinium-225ac-oxodotreotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06590857-9190@assetmemo.bio
DTSTAMP:20261121T005038Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Actinium (225Ac) oxodotreotide: Phase 1/2 readout est. (NCT06590857
 )
DESCRIPTION:Actinium (225Ac) oxodotreotide\, phase 1/2\, HR+/HER2- Metastat
 ic Breast Cancer.\nStudy: Trial of 225Ac-DOTATATE (RYZ101) in Subjects Wit
 h ER+\, HER2-negative Unresectable or Metastatic Breast Cancer Expressing 
 SSTRs.\nEstimated primary completion: October 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/actinium-225ac-oxodotreotide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06590857
URL:https://assetmemo.bio/drug/actinium-225ac-oxodotreotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
